XML 54 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Convertible Preferred Stock
Series B-2 Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Convertible preferred stock, beginning balance (in shares) at Dec. 31, 2016   58,600,315          
Convertible preferred stock, beginning balance at Dec. 31, 2016   $ 348,673          
Increase (Decrease) in Temporary Equity [Roll Forward]              
Issuance of convertible preferred stock, net of issuance costs (in shares)     1,764,705        
Issuance of convertible preferred stock, net of issuance costs     $ 29,927        
Conversion of Series A and B convertible preferred stock into common stock (in shares)   (60,365,020)          
Conversion of Series A and B convertible preferred stock into common stock   $ (378,600)          
Convertible preferred stock, ending balance (in shares) at Dec. 31, 2017   0          
Convertible preferred stock, ending balance at Dec. 31, 2017   $ 0          
Common stock, shares outstanding beginning balance (in shares) at Dec. 31, 2016       8,597,316      
Beginning balance at Dec. 31, 2016 $ (94,154)     $ 344 $ 9,387 $ (373) $ (103,512)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Convertible preferred stock converted into shares of common stock (in shares)       60,365,020      
Convertible preferred stock converted into shares of common stock 378,600     $ 604 377,996    
Issuance of common stock upon initial public offering, net of issuance costs (in shares)       15,972,221      
Issuance of common stock upon initial public offering, net of issuance costs 264,261     $ 160 264,101    
Issuance of common stock upon exercise of stock options (in shares)       648,317      
Issuance of common stock upon exercise of stock options 733     $ 25 708    
Issuance of reversed common stock as consideration in asset acquisition (in shares)       81,164      
Issuance of reserved common stock as consideration in asset acquisition 0     $ 1 (1)    
Vesting of early exercised common stock (in shares)       187,500      
Vesting of early exercised common stock 127     $ 6 121    
Vesting of restricted stock awards (in shares)       1,628,824      
Vesting of restricted stock awards 0     $ 61 (61)    
Stock-based compensation 4,409       4,409    
Net loss (88,185)           (88,185)
Other comprehensive income (loss) 5         5  
Common stock, shares outstanding ending balance (in shares) at Dec. 31, 2017       87,480,362      
Ending balance at Dec. 31, 2017 465,796     $ 1,201 656,660 (368) (191,697)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock in connection with Takeda Collaboration Agreement (in shares)       4,214,559      
Issuance of common stock in connection with the Takeda Collaboration Agreement 94,406     $ 42 94,364    
Issuances under equity incentive plans (in shares)       792,939      
Issuances under equity incentive plans 3,999     $ 8 3,991    
Vesting of early exercised common stock (in shares)       234,372      
Vesting of early exercised common stock 374     $ 3 371    
Vesting of restricted stock awards (in shares)       1,940,203      
Vesting of restricted stock awards 0     $ 19 (19)    
Stock-based compensation 18,791       18,791    
Net loss (36,240)           (36,240)
Other comprehensive income (loss) $ (281)         (281)  
Common stock, shares outstanding ending balance (in shares) at Dec. 31, 2018 94,662,435     94,662,435      
Ending balance at Dec. 31, 2018 $ 546,845     $ 1,273 774,158 (649) (227,937)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock upon exercise of stock options (in shares) 786,638            
Issuances under equity incentive plans (in shares)       973,012      
Issuances under equity incentive plans $ 6,190     $ 9 6,181    
Vesting of early exercised common stock (in shares)       135,424      
Vesting of early exercised common stock 92     $ 2 90    
Vesting of restricted stock awards (in shares)       419,064      
Vesting of restricted stock awards 0     $ 4 (4)    
Stock-based compensation 38,378       38,378    
Net loss (197,614)           (197,614)
Other comprehensive income (loss) $ 999         999  
Common stock, shares outstanding ending balance (in shares) at Dec. 31, 2019 96,189,935     96,189,935      
Ending balance at Dec. 31, 2019 $ 394,890     $ 1,288 $ 818,803 $ 350 $ (425,551)